Lilly Singh is stepping from YouTube stand-out to host on NBC late-night, replacing Carson Daly. Singh, 30, announced her new show, “A Little Late With Lilly Singh," while a guest on "The ...

The Vanity Fair Oscar after-party is always a star-studded affair, and this year’s celebration at the Wallis Annenberg Center for the Performing Arts in Beverly Hills was no exception.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year ...

Eli Lilly plans to move to a second Phase III trial for its oral GLP-1, while Novo Nordisk’s pill version of Wegovy also continues its path toward FDA approval.

Alexa Bliss has been back in WWE for several months now, but fans have yet to see the full return of the twisted Bliss that took a hiatus from the company follo ...

The newest BTK inhibitor, Eli Lilly’s Jaypirca, has shown its chops in a head-to-head trial against the oldest BTK, AbbVie and J&J's Imbruvica.

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.

Eli Lilly said on Tuesday its drug for a type of blood cancer was more effective in a head-to-head study against AbbVie's Imbruvica when tested in both untreated and previously treated patients.

With the next generation of drugs in development amidst an ever-changing environment, here’s what we think of Lilly stock.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.